Adult Biomarkers in Neonatal Brain Injury and Development

新生儿脑损伤和发育中的成人生物标志物

基本信息

  • 批准号:
    10006591
  • 负责人:
  • 金额:
    $ 53.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-09-01 至 2022-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary Circulating brain injury biomarkers have been studied extensively in adults, yet we have no clinically available biomarkers to acutely identify brain specific injury common in neonates, such as intraventricular hemorrhage (IVH) and neonatal hypoxic-ischemic encephalopathy (HIE), to follow therapeutic efficacy or evaluate new therapies in neonates at risk. Hurdles to adoption of brain injury biomarkers in the NICU have been the lack of normative data in the growing infant, effect of prematurity, relatively large sample volumes needed and no large studies with external validation. The overall goal of this proposal is to develop a multimarker circulating brain injury biomarker panel for neonatal IVH and HIE using well studied adult biomarkers, to provide a benchmark of therapeutic efficacy for current standard treatments and future investigational treatments, and to provide early prognostic information. The central hypothesis of this proposal is that circulating brain specific protein levels measured serially over days 0-7 of life in premature neonates and neonates with HIE will provide early injury detection, predict infants at risk for death or moderate-severe neurologic disability, predict therapeutic efficacy for therapeutic hypothermia, and serve as a basis for triaging neonates to appropriate new investigational therapies to decrease morbidity and improve outcomes. To examine our hypothesis we will utilize a novel multiplex panel of 4 brain specific proteins (BDNF, S100B, NSE and GFAP) and 4 brain injury related proteins (IL-1, IL-6, IL-8, VEGF) studied extensively in adults as biomarkers of brain injury, in training (Johns Hopkins Medicine, Baltimore, JHM) and external test (All Children’s Hospital JHM, St. Petersburg, FL) cohorts in the following Specific Aims: 1) Determine if circulating levels of brain injury biomarkers are dependent on gestational age using an existing cohort of longitudinal blood samples from premature and full term infants (N=400, 23-40 weeks gestation) admitted to the NICU without clinical brain injury to determine the effect of gestational age on baseline levels. 2) Determine in HIE if circulating brain injury biomarker levels during and after therapeutic hypothermia predict adverse outcomes including A) MRI abnormalities at 7-10 days and B) death or neurologic disability at 24 months. 3) Determine in IVH if circulating brain injury biomarker levels during the first 7 days of life in VLBW premature neonates are A) diagnostic for IVH, B) predict PVWMI brain injury at 6 weeks and C) neurologic disability at 24 months. Both of these aims will use concurrent IVH and HIE enrollment at JHM (training set) and ACH JHM (test set) for external validation. By focusing on a panel of blood brain barrier dependent and independent biomarker proteins studied exhaustively in adults, in a innovative and highly sensitive multiplex Pharma grade format, using large training and test cohorts we will confirm generalizability and efficacy in neonatal brain injury.
项目摘要 循环脑损伤生物标志物已在成人中进行了广泛的研究,但我们没有临床可用的 用于急性识别新生儿常见脑特异性损伤(例如脑室内出血)的生物标志物 (IVH)和新生儿缺氧缺血性脑病(HIE),以跟踪治疗效果或评估新的 治疗高危新生儿。在NICU中采用脑损伤生物标志物的障碍是缺乏 生长期婴儿的规范性数据,早产的影响,需要相对较大的样本量, 外部验证的研究。这项提案的总体目标是开发一种多标记循环脑 新生儿IVH和HIE的损伤生物标志物面板,使用充分研究的成人生物标志物,以提供 目前标准治疗和未来研究治疗的疗效,并提供早期 预测信息这项提议的核心假设是,循环脑中特定的蛋白质水平 在早产儿和HIE新生儿的0-7天内连续测量可提供早期损伤 检测,预测婴儿死亡或中重度神经功能障碍的风险,预测治疗效果 用于治疗性低温,并作为将新生儿分诊到适当的新研究的基础。 降低发病率和改善结果的治疗。为了检验我们的假设,我们将利用一本小说, 4种脑特异性蛋白(BDNF、S100 B、NSE和GFAP)和4种脑损伤相关蛋白的复合组 (IL-1 IL-6、IL-8、VEGF)作为脑损伤的生物标志物在训练中在成人中被广泛研究(Johns霍普金斯 Medicine,巴尔的摩,JHM)和外部测试(All Children's Hospital JHM,St.彼得堡,FL)队列。 1)确定脑损伤生物标志物的循环水平是否依赖于 使用来自早产儿和足月儿的纵向血液样本的现有队列的胎龄 (N=400,妊娠23-40周)入住NICU,无临床脑损伤,以确定 胎龄在基线水平。2)在HIE中确定循环脑损伤生物标志物水平, 治疗性低温后预测不良结局,包括A)7-10天时的MRI异常和B) 24个月时死亡或神经系统残疾。3)在IVH中确定循环脑损伤生物标志物水平是否在 VLBW早产新生儿出生后的前7天A)诊断IVH,B)预测6岁时PVH脑损伤 C)24个月时的神经功能障碍。这两个目标都将同时使用IVH和HIE入组 在JHM(训练集)和ACH JHM(测试集)进行外部验证。通过研究血脑屏障 依赖和独立的生物标志物蛋白质在成人中进行了详尽的研究, 敏感的多重制药级格式,使用大型培训和测试队列,我们将确认可推广性 和治疗新生儿脑损伤的疗效。

项目成果

期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Blood biomarkers for neonatal hypoxic-ischemic encephalopathy in the presence and absence of sentinel events.
Interaction of hydrocortisone and illness severity on head growth in cohort of ELBW infants.
氢化可的松与疾病严重程度对 ELBW 婴儿头部生长的相互作用。
  • DOI:
    10.1038/s41390-023-02689-w
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    Chen,Haiwen;Aziz,KhyzerB;Spahic,Harisa;Miller,Sarah;Guryildirim,Melike;Sellers,Austin;Brooks,Sandra;Kilborn,Alison;Everett,AllenD;Northington,FrancesJ;Stafstrom,CarlE;Chavez-Valdez,Raul
  • 通讯作者:
    Chavez-Valdez,Raul
Perinatal blood biomarkers for the identification of brain injury in very low birth weight growth-restricted infants.
Post-operative acute kidney injury is associated with a biomarker of acute brain injury after paediatric cardiac surgery.
术后急性肾损伤与小儿心脏手术后急性脑损伤的生物标志物相关。
  • DOI:
    10.1017/s1047951120000451
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    1
  • 作者:
    Parsons,Michael;Greenberg,Jason;Parikh,Chirag;Brown,Jeremiah;Parker,Devin;Zhu,Jie;Vricella,Luca;Everett,AllenD
  • 通讯作者:
    Everett,AllenD
Correction to: Clonidine for sedation in infants during therapeutic hypothermia with neonatal encephalopathy: pilot study.
更正:可乐定在新生儿脑病低温治疗期间用于婴儿镇静:初步研究。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALLEN D EVERETT其他文献

COMPARISON BETWEEN PULMONARY ARTERIAL HYPERTENSION (PAH) RISK ASSESSMENT METHODS, INCLUDING PULMONARY HYPERTENSION OUTCOME RISKS ASSESSMENT (PHORA)
  • DOI:
    10.1016/j.chest.2022.08.2013
  • 发表时间:
    2022-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    CHARLES FAUVEL;ZILU LIU;SHILI LIN;PRISCILLA CORREA-JAQUE;AMY WEBB;REBECCA R VANDERPOOL;MANREET KANWAR;JIDAPA KRAISANGKA;PUNEET MATHUR;ADAM PERER;ALLEN D EVERETT;RAYMOND L BENZA
  • 通讯作者:
    RAYMOND L BENZA

ALLEN D EVERETT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALLEN D EVERETT', 18)}}的其他基金

Role of Cyclohexanone Toxicity in Mediating Congenital Cardiac Surgery Outcomes
环己酮毒性在调节先天性心脏手术结果中的作用
  • 批准号:
    10627951
  • 财政年份:
    2022
  • 资助金额:
    $ 53.05万
  • 项目类别:
Role of Cyclohexanone Toxicity in Mediating Congenital Cardiac Surgery Outcomes
环己酮毒性在调节先天性心脏手术结果中的作用
  • 批准号:
    10444513
  • 财政年份:
    2022
  • 资助金额:
    $ 53.05万
  • 项目类别:
Advanced therapeutic hypothermia efficacy network modeling in neonatal HIE
新生儿 HIE 的先进低温治疗功效网络模型
  • 批准号:
    10538972
  • 财政年份:
    2022
  • 资助金额:
    $ 53.05万
  • 项目类别:
Advanced therapeutic hypothermia efficacy network modeling in neonatal HIE
新生儿 HIE 的先进低温治疗功效网络模型
  • 批准号:
    10696194
  • 财政年份:
    2022
  • 资助金额:
    $ 53.05万
  • 项目类别:
Role of IGF axis in pulmonary hypertension
IGF轴在肺动脉高压中的作用
  • 批准号:
    10402941
  • 财政年份:
    2020
  • 资助金额:
    $ 53.05万
  • 项目类别:
Role of IGF axis in pulmonary hypertension
IGF轴在肺动脉高压中的作用
  • 批准号:
    10191028
  • 财政年份:
    2020
  • 资助金额:
    $ 53.05万
  • 项目类别:
Role of IGF axis in pulmonary hypertension
IGF轴在肺动脉高压中的作用
  • 批准号:
    10687923
  • 财政年份:
    2020
  • 资助金额:
    $ 53.05万
  • 项目类别:
Clinical and mechanistic role of HDGF in pulmonary hypertension
HDGF 在肺动脉高压中的临床和机制作用
  • 批准号:
    9772631
  • 财政年份:
    2017
  • 资助金额:
    $ 53.05万
  • 项目类别:
Adult Biomarkers in Neonatal Brain Injury and Development
新生儿脑损伤和发育中的成人生物标志物
  • 批准号:
    9761549
  • 财政年份:
    2016
  • 资助金额:
    $ 53.05万
  • 项目类别:
Adult Biomarkers in Neonatal Brain Injury and Development
新生儿脑损伤和发育中的成人生物标志物
  • 批准号:
    9549109
  • 财政年份:
    2016
  • 资助金额:
    $ 53.05万
  • 项目类别:

相似海外基金

Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 53.05万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 53.05万
  • 项目类别:
    Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 53.05万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 53.05万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 53.05万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 53.05万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 53.05万
  • 项目类别:
    Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 53.05万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 53.05万
  • 项目类别:
    EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 53.05万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了